Bifogade filer
New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency
Kurs
+0,17%
Likviditet
2,32 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-05-06 | N/A | Årsstämma |
| 2025-04-30 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | 07:00 | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-25 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-07 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2024-05-06 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-28 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2023-04-27 | - | Årsstämma |
| 2023-04-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-11-08 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-30 | - | Årsstämma |
| 2022-05-11 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2022-04-26 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-13 | - | Extra Bolagsstämma 2022 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-30 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-12-11 | - | Extra Bolagsstämma 2020 |
| 2020-11-04 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-24 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2020-04-23 | - | Årsstämma |
| 2020-04-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-18 | - | Bokslutskommuniké 2019 |
| 2019-10-23 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2019-05-07 | - | Årsstämma |
| 2019-05-06 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-10-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-25 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2018-04-24 | - | Årsstämma |
| 2018-04-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-10-20 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-26 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2017-04-25 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2017-02-10 | - | Extra Bolagsstämma 2017 |
| 2016-11-07 | - | Extra Bolagsstämma 2016 |
| 2016-10-20 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-15 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2016-04-14 | - | Årsstämma |
| 2016-02-29 | - | Bokslutskommuniké 2015 |
| 2015-10-20 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-18 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-21 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-15 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2015-04-14 | - | Årsstämma |
| 2015-02-17 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Extra Bolagsstämma 2014 |
| 2014-10-24 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-28 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-25 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-09 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2014-04-08 | - | Årsstämma |
| 2014-02-19 | - | Bokslutskommuniké 2013 |
| 2013-10-25 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-29 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-19 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2013-04-18 | - | Årsstämma |
| 2013-04-18 | - | Extra Bolagsstämma 2013 |
| 2013-04-18 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-02-21 | - | Bokslutskommuniké 2012 |
| 2012-10-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-24 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-30 | - | X-dag ordinarie utdelning EGTX 0.00 SEK |
| 2012-03-29 | - | Årsstämma |
| 2012-02-17 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-25 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
- An Abstract by Dr M. Freund and co-authors from Erasmus Medical Center, Rotterdam, The Netherlands, published ahead of the Annual Meeting of the European Thyroid Association reports that treatment with the investigational drug tiratricol exerts beneficial effects on several patient-centered outcome measures in MCT8 deficiency.
Stockholm, Sweden, August 28, 2024. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), today announced the content of an Abstract by Matthijs Freund and co-authors, Erasmus Medical Center, Rotterdam, The Netherlands, published ahead of the 46th Annual Meeting of the European Thyroid Association, to be held in Athens, Greece, on September 7-10, 2024. In this analysis the authors performed post-hoc analyses on caregiver-reported patient-centered outcome measures in the Triac Trial I (1). In this trial, 40 patients with MCT8 deficiency completed 1 year of tiratricol treatment. At baseline, during clinical visits and at the end of the study, semi-structured interviews were held with caregivers on complex needs and daily care challenges, including motor skills, sleep problems, and seizure frequency. Moreover, parents were asked to report perceived changes in (thyrotoxic) symptoms such as increased sweating and reduction in salivary flow.
According to the Abstract, there were improvements upon tiratricol treatment reported by caregivers related to improved interaction (22/39), greater alertness (19/39), improved motor skills (12/39), improved head control (7/39), and improved sleep (8/39). For 1 patient, also negative changes were reported, specifically increased constipation and higher unsettledness. Compared to the baseline visit, excessive sweating was much less reported (48.6% vs. 8.1%) and less reduction in salivary flow was observed (30.6% vs. 22.2%) by the caregivers at the end study visit. Seizures and continence were reportedly unchanged. All parents (40/40) preferred to continue tiratricol treatment.
Results from the analysis will be presented as an oral presentation by Dr Matthijs Freund on September 9, 2024, at the 46th Annual Meeting of the European Thyroid Association, in Athens, Greece.
Link to Abstract: Freund. M. et al. Effect of the T3 analogue Triac on patient-centered outcome measures in patients with MCT8 deficiency: post-hoc analysis of the international Triac Trial I
Link to presentation session: https://apps.m-anage.com/eta2024/en-GB/pag/presentation/673266
(1) Groeneweg, S. et al. Lancet Diabetes Endocrinol (2019) 7(9):695-706
For further information, please contact:
Nicklas Westerholm, CEO
+46 (0) 733 542 062
nicklas.westerholm@egetis.com
Karl Hård, Head of Investor Relations & Business Development
+46 (0) 733 011 944
karl.hard@egetis.com
About Egetis Therapeutics
Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company’s lead drug candidate Emcitate® (tiratricol) is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. Egetis submitted a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in October 2023.
After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis will update the market as soon as recruitment has been completed and at that point inform about the timing of availability of top-line results, and the expected timing of the subsequent NDA filing.
Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Emcitate has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.
The drug candidate Aladote® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The study start has been postponed until Emcitate marketing authorization submissions for MCT8 deficiency have been completed. Aladote has been granted ODD in the US and in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com